Research Terms
These sigma receptors and opioid receptor modulators present improved metabolic stability and bioavailability for treating opioid addiction. While opioid preparations such as morphine have been mainstays for pain management since the early 1800s, overprescribing of both natural and semi synthetic opioids has fueled the ongoing opioid epidemic in the United States. Today, substance use disorder and opioid addiction remain critical public health challenges with millions of Americans diagnosed with Opioid Use Disorder (OUD). The global OUD market is projected to grow from USD 3.92 billion this year to USD 7.51 billion by 2032, which is a compound annual growth rate (CAGR) of 9.7% with North America accounting for nearly 77% of the market share.
Although several medications are available for OUD, their use is often limited by underutilization, risk of side effects, and incomplete control of cravings and withdrawal symptoms. Current pharmacological options, such as opioid agonists, antagonists, and alpha-2 adrenergic agents, require careful dose management, can carry risks of misuse or respiratory depression, and may not fully address the complex neurobiology of addiction and relapse. Sigma receptors, a distinct class of receptors highly expressed in the central nervous system, have emerged as promising new targets in the fight against substance use disorders. Unlike traditional opioid receptors, sigma receptors are involved in modulating neurotoxicity, drug-seeking behavior, and withdrawal symptoms.
Researchers at the University of Florida have developed a new class of small-molecule sigma receptor agonists with exceptional metabolic stability, oral bioavailability, and brain penetration. By selectively modulating sigma receptors, these compounds offer a new therapeutic strategy to reduce substance intake, mitigate neurotoxic damage, and improve long-term outcomes for individuals with opioid use disorder. This technology represents a significant advancement, addressing both the underlying biology of addiction and the practical challenges of current OUD treatments.
Therapeutic drug candidates treat and prevent opioid use disorder by reducing withdrawal symptoms and mitigating neurotoxic effects associated with substance use and addiction
This dual-action therapeutic platform integrates two classes of small molecules designed to address the complex neurobiology of opioid addiction. University of Florida researchers have developed small molecules that target sigma receptors and opioid/adrenergic pathways to address opioid addiction. The first class consists of metabolically stable dual sigma-1 and sigma-2 receptor antagonists designed to prevent and treat substance intake. By selectively blocking sigma receptors, which are key modulators widely distributed in the central nervous system, these molecules are engineered to disrupt the reinforcing effects of opioids and psychostimulants, as well as reduce addiction-related psychiatric symptoms such as craving and anxiety.
The second class features synthetic analogs of mitragynine, the main alkaloid in kratom, that bind to Mu and kappa opioid receptors as well as alpha-2 adrenergic receptors. These compounds are rationally designed to engage both mu and kappa opioid receptors and alpha-2 adrenergic receptors, uniting two mechanisms that are typically targeted with separate medications in current opioid dependence and withdrawal management. Functioning as agonists at opioid receptors, these analogs are intended to provide effective withdrawal relief while minimizing the risk of severe respiratory depression, which is a major limitation of traditional opioid therapies. By offering pharmaceutical purity and predictable pharmacokinetics, these analogs replicate the beneficial aspects of kratom’s traditional use in a controlled, consistent form. Together, these compounds create a platform for developing safer alternatives to current opioid addiction treatments, addressing both the neurological basis of addiction and the physical symptoms of withdrawal.
A compound that binds to sigma receptors can treat and prevent viral infections, such as SARS-CoV-2 (COVID-19), and their symptoms. COVID-19 was first detected in December 2019 in Wuhan, China. In January 2020, the first cases in the United States (U.S.) were reported. More than a million in the U.S. and six million globally have died due to COVID-19 infections or complications. Developing treatments to fight COVID-19 has been a top priority for medical researchers, academia, and pharmaceutical companies. Currently, a limited number of anti-viral treatments are readily available for treating COVID-19 and the symptoms associated with it.
Researchers at the University of Florida have developed compounds that bind to sigma receptors which can be administered orally, nasally, ophthalmically, or injected to treat and prevent SARS-CoV-2 (COVID-19). These compounds target surface proteins found in SARS-CoV-2 and many other viruses, such as Hepatitis C. This gives the immune system time to respond to infection. It also provides the ability to treat and prevent respiratory, pulmonary, cardiovascular, or metabolic symptoms or dysfunction associated with COVID-19 infection while slowing down viral effects on the cells.
Sigma receptor binding compounds for treating and preventing COVID-19 and the symptoms associated with infection
These antiviral compounds are sigma receptor ligands and modulates proteins found on the cell surface that mediate the early stages of viral RNA replication. Targeting these receptors interferes with early virus reprogramming of cells and gives the immune system more time to respond, especially in vaccinated individuals. Sigma receptor compounds exhibit antiviral properties against SARS-CoV-2 and could inhibit COVID-19 mediated cell death, intracellular replication, and infectivity.
